MetaVia's Obesity Drug DA-1726 Accepted for Late-Breaking Poster at EASL Congress
Summary
MetaVia announced that a late-breaking abstract for its obesity drug candidate, DA-1726, has been accepted for a poster presentation at the upcoming European Association for the Study of the Liver (EASL) Congress, providing further visibility for the asset.
Key Events
-
Abstract Accepted for Major Conference
A late-breaking abstract highlighting DA-1726, MetaVia's novel dual GLP-1/glucagon analog for obesity, has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026.
-
Presentation Scheduled
The poster presentation is scheduled for May 27-30, 2026, in Barcelona, Spain, with MetaVia's Chief Medical Officer, Chris Fang, listed as the presenting author.
-
Ongoing Clinical Development
DA-1726 is currently being evaluated in a 16-week Phase 1 Part 3 titration study, with data from this study anticipated in the fourth quarter of 2026.
Analysis
For a clinical-stage biotechnology company like MetaVia, the acceptance of a late-breaking abstract for a key pipeline asset at a major medical conference like EASL is an important positive development. It increases the visibility and scientific validation of DA-1726, their dual GLP-1/glucagon analog for obesity. This news provides a positive clinical update amidst the company's ongoing financial challenges, including a going concern warning and a proposed reverse stock split, potentially boosting investor sentiment by highlighting pipeline progress.
At the time of this filing, MTVA was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $1.00 to $19.03. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.